Search

Amber D. Steele

Examiner (ID: 2430, Phone: (571)272-5538 , Office: P/1676 )

Most Active Art Unit
1658
Art Unit(s)
1654, 1639, 1658, 1676
Total Applications
1302
Issued Applications
628
Pending Applications
166
Abandoned Applications
538

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17890747 [patent_doc_number] => 11453700 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-27 [patent_title] => Peptide having activities of skin whitening and uses thereof [patent_app_type] => utility [patent_app_number] => 16/625841 [patent_app_country] => US [patent_app_date] => 2019-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 4 [patent_no_of_words] => 4018 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16625841 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/625841
Peptide having activities of skin whitening and uses thereof Oct 9, 2019 Issued
Array ( [id] => 17336014 [patent_doc_number] => 20220002345 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => Bone-Targeting Therapeutic Compositions and Methods of Using Them [patent_app_type] => utility [patent_app_number] => 17/283312 [patent_app_country] => US [patent_app_date] => 2019-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3388 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283312 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/283312
Bone-Targeting Therapeutic Compositions and Methods of Using Them Oct 7, 2019 Abandoned
Array ( [id] => 19367390 [patent_doc_number] => 12059450 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-13 [patent_title] => Anticancer pharmaceutical composition containing IF1 as active ingredient [patent_app_type] => utility [patent_app_number] => 17/281808 [patent_app_country] => US [patent_app_date] => 2019-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 6174 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17281808 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/281808
Anticancer pharmaceutical composition containing IF1 as active ingredient Oct 1, 2019 Issued
Array ( [id] => 17426065 [patent_doc_number] => 20220053773 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOGENIC INFECTIONS IN PLANTS [patent_app_type] => utility [patent_app_number] => 17/281884 [patent_app_country] => US [patent_app_date] => 2019-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37290 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17281884 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/281884
COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOGENIC INFECTIONS IN PLANTS Sep 30, 2019 Pending
Array ( [id] => 16191109 [patent_doc_number] => 20200231958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION [patent_app_type] => utility [patent_app_number] => 16/589851 [patent_app_country] => US [patent_app_date] => 2019-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11967 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16589851 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/589851
FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION Sep 30, 2019 Abandoned
Array ( [id] => 20621654 [patent_doc_number] => 12589148 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-31 [patent_title] => Immunity-inducing agent comprising antigen peptide-adjuvant nucleotide conjugate and pharmaceutical composition comprising same [patent_app_type] => utility [patent_app_number] => 17/280605 [patent_app_country] => US [patent_app_date] => 2019-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 7 [patent_no_of_words] => 6896 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 190 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17280605 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/280605
Immunity-inducing agent comprising antigen peptide-adjuvant nucleotide conjugate and pharmaceutical composition comprising same Sep 26, 2019 Issued
Array ( [id] => 17198493 [patent_doc_number] => 20210338587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => INJECTABLE COMPOSITION [patent_app_type] => utility [patent_app_number] => 17/279807 [patent_app_country] => US [patent_app_date] => 2019-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17932 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17279807 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/279807
INJECTABLE COMPOSITION Sep 26, 2019 Abandoned
Array ( [id] => 15361495 [patent_doc_number] => 20200016512 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => AFFINITY SEPARATION MATRIX FOR PURIFYING IMMUNOGLOBULIN [patent_app_type] => utility [patent_app_number] => 16/586054 [patent_app_country] => US [patent_app_date] => 2019-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10155 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16586054 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/586054
AFFINITY SEPARATION MATRIX FOR PURIFYING IMMUNOGLOBULIN Sep 26, 2019 Abandoned
Array ( [id] => 17398165 [patent_doc_number] => 20220040255 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => CHEMOTHERAPEUTIC REMODELING OF THE GUT MICROBIOME [patent_app_type] => utility [patent_app_number] => 17/280660 [patent_app_country] => US [patent_app_date] => 2019-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17089 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17280660 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/280660
CHEMOTHERAPEUTIC REMODELING OF THE GUT MICROBIOME Sep 25, 2019 Abandoned
Array ( [id] => 15960569 [patent_doc_number] => 20200164036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => METHODS FOR TREATMENT OF BILE ACID-RELATED DISORDERS AND PREDICTION OF CLINICAL SENSITIVITY TO TREATMENT OF BILE ACID-RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 16/562150 [patent_app_country] => US [patent_app_date] => 2019-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47968 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16562150 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/562150
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders Sep 4, 2019 Issued
Array ( [id] => 17156120 [patent_doc_number] => 20210317171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => RECOMBINANT LECTIN VARIANTS [patent_app_type] => utility [patent_app_number] => 17/272090 [patent_app_country] => US [patent_app_date] => 2019-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14608 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17272090 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/272090
Recombinant lectin variants Aug 29, 2019 Issued
Array ( [id] => 17200119 [patent_doc_number] => 20210340214 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEIN DOSING REGIMENS [patent_app_type] => utility [patent_app_number] => 17/271792 [patent_app_country] => US [patent_app_date] => 2019-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16891 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271792 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/271792
CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEIN DOSING REGIMENS Aug 27, 2019 Abandoned
Array ( [id] => 17170354 [patent_doc_number] => 20210324024 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => ENGINEERED SEMAPHORINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/271380 [patent_app_country] => US [patent_app_date] => 2019-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19036 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271380 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/271380
ENGINEERED SEMAPHORINS AND USES THEREOF Aug 26, 2019 Abandoned
Array ( [id] => 16877996 [patent_doc_number] => 11028129 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-06-08 [patent_title] => Compositions for expanding regulatory T cells (Treg) populations, and treating and ameliorating autoimmune diseases and conditions [patent_app_type] => utility [patent_app_number] => 16/542168 [patent_app_country] => US [patent_app_date] => 2019-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 26 [patent_no_of_words] => 20523 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16542168 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/542168
Compositions for expanding regulatory T cells (Treg) populations, and treating and ameliorating autoimmune diseases and conditions Aug 14, 2019 Issued
Array ( [id] => 17657068 [patent_doc_number] => 20220177533 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => Recombinant TGF a for wound healing purposes, and the process thereof [patent_app_type] => utility [patent_app_number] => 17/266898 [patent_app_country] => US [patent_app_date] => 2019-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5791 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17266898 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/266898
Recombinant TGF a for wound healing purposes, and the process thereof Aug 7, 2019 Pending
Array ( [id] => 17990180 [patent_doc_number] => 20220356217 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => Polypeptide Integrin Antagonists [patent_app_type] => utility [patent_app_number] => 17/266339 [patent_app_country] => US [patent_app_date] => 2019-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18901 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17266339 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/266339
Polypeptide integrin antagonists Aug 7, 2019 Issued
Array ( [id] => 18027826 [patent_doc_number] => 11510987 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-29 [patent_title] => Endocytosis enhancer for drug delivery system [patent_app_type] => utility [patent_app_number] => 16/426184 [patent_app_country] => US [patent_app_date] => 2019-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 49 [patent_no_of_words] => 11657 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16426184 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/426184
Endocytosis enhancer for drug delivery system Aug 6, 2019 Issued
Array ( [id] => 15147741 [patent_doc_number] => 20190352348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-21 [patent_title] => PEPTIDES AND METHODS FOR THE TREATMENT OF DIABETES [patent_app_type] => utility [patent_app_number] => 16/531276 [patent_app_country] => US [patent_app_date] => 2019-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12409 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16531276 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/531276
Peptides and methods for the treatment of diabetes Aug 4, 2019 Issued
Array ( [id] => 16060971 [patent_doc_number] => 10689417 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-23 [patent_title] => IL-2Rg binding compounds [patent_app_type] => utility [patent_app_number] => 16/531989 [patent_app_country] => US [patent_app_date] => 2019-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 16 [patent_no_of_words] => 111100 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16531989 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/531989
IL-2Rg binding compounds Aug 4, 2019 Issued
Array ( [id] => 16868546 [patent_doc_number] => 20210162013 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-03 [patent_title] => COMPOSITIONS AND METHODS FOR IMPROVING THE BIOAVAILABILITY OF GLP1 AND ANALOGUES THEREOF [patent_app_type] => utility [patent_app_number] => 17/265747 [patent_app_country] => US [patent_app_date] => 2019-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14511 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17265747 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/265747
COMPOSITIONS AND METHODS FOR IMPROVING THE BIOAVAILABILITY OF GLP1 AND ANALOGUES THEREOF Aug 4, 2019 Abandoned
Menu